λ©ν λλ―Ό ννΈλ μ΄νΈ
**λ©ν λλ―Ό ννΈλ μ΄νΈ**λ μ£Όλ‘ μ¬λ°μ± μλ‘ κ°μΌ(UTI) μλ°©μ μ¬μ©λλ μλ‘ λ°©λΆμ μ λλ€. * **μμμ μ μ©μ±:** μμνμμ 1μ°¨ μ½λ¬Όλ‘ νν μ¬μ©λμ§ μμΌλ©°, κ°μ κ³ μμ΄μμμ ν¨λ₯μ νμΈνλ νμ€ν μ¦κ±°λ μ νμ μ λλ€. μΌλ°μ μΌλ‘ κΈ°μ‘΄ νμμ μΉλ£κ° μ€ν¨νκ±°λ κΈκΈ°μΈ λ΄μ±μ΄ κ°ν μ¬λ°μ± νλΆ μλ‘ κ°μΌμ 보λ₯λ©λλ€. * **κΈ°μ μμ‘΄μ±:** κ·Έ ν¨λ₯μ μ°μ± μλ‘ νκ²½(pH < 6.5, μ΄μμ μΌλ‘λ < 5.5)μ μ격νκ² μμ‘΄ν©λλ€. μμΉΌλ¦¬μ± μλ³μμλ μ½λ¬Όμ΄ λΉνμ± μνλ‘ μ μ§λ©λλ€. * **νκ· μ€ννΈλΌ:** νμ±νλλ©΄ κ·Έλ μμ±κ· (*ν¬λμκ΅¬κ· *, *μ₯κ΅¬κ· *) λ° κ·Έλ μμ±κ· (*λμ₯κ· *, *μλλͺ¨λμ€*, *νλ‘ν μ°μ€*) λͺ¨λμ λν΄ κ΄λ²μνκ³ λΉνΉμ΄μ μΈ μ΄κ· νμ±μ μ 곡νλ©°, μΌλΆ μ§κ· λ³μ체μλ ν¨κ³Όκ° μλ κ²μΌλ‘ λ³΄κ³ λμμ΅λλ€. * **μμμ μ§μ£Ό:** ν¬λ¦μλ°νλλ‘ μ νλκΈ° λλ¬Έμ μΈκ· μ νλΌμ€λ―Έλ λ§€κ° λλ μΌμ체 λ΄μ±μ λ°μμν€μ§ μμ λ§μ± μλ°©μ μμ΄ λ 보μ μΈ κ°μΉλ₯Ό μ§λλλ€.
μμ© κΈ°μ : Methenamine is a prodrug that requires an acidic environment for activation. * **Hydrolysis Pathway:** In an acidic urinary environment (pH < 6.5) β **methenamine** is hydrolyzed β **formaldehyde** + **ammonia**. * **Bactericidal Action:** **Formaldehyde** acts as a non-specific bactericidal agent by denaturing bacterial proteins and nucleic acids. * **Role of Hippurate:** The **hippuric acid** salt component serves a dual purpose: it acts as a weak acid to help lower the urinary pH (facilitating the conversion to formaldehyde) and possesses mild, non-specific antibacterial activity of its own. * **Systemic Inactivity:** At physiological blood pH (7.4), methenamine remains stable and inactive, ensuring that formaldehyde is only generated locally within the urinary bladder.
λλ¬Ό μ’ λ³ μ©λ
- Urinary tract infection prophylaxis Β· 250 mg Β· PO Β· q12h Β· Methenamine hippurate
- Urinary tract infection prophylaxis Β· 10 mg/kg Β· PO Β· q6h Β· Methenamine mandelate; use with ammonium chloride to acidify urine and increase effectiveness
- Urinary tract infection prophylaxis Β· 10 mg/kg Β· PO Β· q6h Β· Methenamine mandelate
- Urinary tract infection prophylaxis Β· 10-20 mg/kg Β· PO Β· q8-12h Β· Methenamine mandelate; urine pH may need to be lowered by use of an acidifying diet and/or urinary acidifiers
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to methenamine or its salts
- Renal insufficiency
- Metabolic acidosis
- Severe hepatic impairment (due to ammonia production during hydrolysis)
- Severe dehydration
μ΄μλ°μ
- Gastrointestinal irritation (nausea, vomiting, anorexia)
- Dysuria (secondary to formaldehyde irritation with long-term use)
- Systemic acidosis (potential)
- Lipoid pneumonitis (reported in humans using oral suspension)
μ½λ¬Ό μνΈμμ©
- Sulfamethiazole Β· Not recommended; an insoluble precipitate may form in the urine.
- Urine Alkalinizing Drugs (e.g., calcium/magnesium antacids, carbonic anhydrase inhibitors, citrates, sodium bicarbonate, thiazide diuretics) Β· May reduce the efficacy of methenamine by preventing its conversion to formaldehyde in the urine.
λͺ¨λν°λ§
- Urine pH (must remain < 6.5)
- Clinical efficacy (resolution or prevention of UTI symptoms)
- Urinalysis and urine cultures
κ³Όμ©λ
Dogs have tolerated single IV dosages of up to 600 mg/kg of methenamine hippurate without overt toxic effects. **Management of Large Oral Overdoses:** * Implement established gut emptying protocols (emesis/gastric lavage) if ingestion is recent. * Maintain hydration status with intravenous fluids. * Provide symptomatic and supportive care as required, monitoring for systemic acidosis and gastrointestinal distress.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.